Skip to main content
Erschienen in: Familial Cancer 4/2009

01.12.2009

Protective effect of copy number polymorphism of glutathione S-transferase T1 gene on melanoma risk in presence of CDKN2A mutations, MC1R variants and host-related phenotypes

verfasst von: Valérie Chaudru, M. T. Lo, F. Lesueur, C. Marian, H. Mohamdi, K. Laud, M. Barrois, A. Chompret, M. F. Avril, F. Demenais, B. Bressac-de Paillerets

Erschienen in: Familial Cancer | Ausgabe 4/2009

Einloggen, um Zugang zu erhalten

Abstract

The effect of CDKN2A, the major high-risk melanoma susceptibility gene, has been shown to be modified by host-related phenotypes and variants of MC1R gene. The glutathione S-transferase (GSTs) genes, implicated in detoxification of metabolites after UV exposure, are candidates for modulating CDKN2A penetrance. Few case-control studies have investigated the effect of GSTs on melanoma risk, and have led to controversial results while these genes have not yet been studied in CDKN2A melanoma-prone families. We examined the effect of GSTP1, GSTM1 and GSTT1 genotypes on melanoma risk in 25 multi-generational melanoma-prone families with CDKN2A mutations, in presence of MC1R gene variants, sun exposure, and host-related phenotypes. These data included 195 genotyped subjects for all studied genes. We applied the GEE (Generalized Estimating Equations) approach to test for the effect of GSTs while adjusting for age, sex and CDKN2A mutation status and including successively MC1R, sun exposure and host factors in the model. No significant effect of null GSTM1 allele and GSTP1 variants (p.I105V, p.A114V) on melanoma risk was found. However, a significant protective effect of carrying ≥1 null GSTT1 allele was shown: ORadjusted for age,sex,CDKN2A  = 0.41 (0.18–0.94) and ORadjusted for age,sex,CDKN2A,MC1R  = 0.24 (0.15–0.58). Altogether, the factors modifying significantly the melanoma risk associated with CDKN2A mutations (stepwise procedure) were: MC1R and dysplastic nevi (increasing the risk) and GSTT1 (decreasing the risk). This study shows that even when a high-risk gene (CDKN2A) has been identified, multiple genetic modifiers influence melanoma risk.
Literatur
4.
Zurück zum Zitat Bishop DT, Demenais F, Goldstein AM et al (2002) Geographical variation in the penetrance of CDKN2A mutations for melanoma. J Natl Cancer Inst 94:894–903PubMed Bishop DT, Demenais F, Goldstein AM et al (2002) Geographical variation in the penetrance of CDKN2A mutations for melanoma. J Natl Cancer Inst 94:894–903PubMed
5.
Zurück zum Zitat Chaudru V, Chompret A, Bressac-de Paillerets B, Spatz A, Avril MF, Demenais F (2004) Influence of genes, nevi, and sun-sensitivity on melanoma risk in a family sample unselected by family history and in melanoma-prone families. J Natl Cancer Inst 96:785–795PubMedCrossRef Chaudru V, Chompret A, Bressac-de Paillerets B, Spatz A, Avril MF, Demenais F (2004) Influence of genes, nevi, and sun-sensitivity on melanoma risk in a family sample unselected by family history and in melanoma-prone families. J Natl Cancer Inst 96:785–795PubMedCrossRef
6.
7.
8.
Zurück zum Zitat Chaudru V, Laud K, Avril MF et al (2005) Melanocortin-1 receptor (MC1R) gene variants and dysplastic nevi modify penetrance of CDKN2A mutations in French melanoma-prone pedigrees. Cancer Epidemiol Biomarkers Prev 14:2384–2390. doi:10.1158/1055-9965.EPI-04-0777 CrossRefPubMed Chaudru V, Laud K, Avril MF et al (2005) Melanocortin-1 receptor (MC1R) gene variants and dysplastic nevi modify penetrance of CDKN2A mutations in French melanoma-prone pedigrees. Cancer Epidemiol Biomarkers Prev 14:2384–2390. doi:10.​1158/​1055-9965.​EPI-04-0777 CrossRefPubMed
9.
Zurück zum Zitat Goldstein AM, Landi MT, Tsang S, Fraser MC, Munroe DJ, Tucker MA (2005) Association of MC1R variants and risk of melanoma in melanoma-prone families with CDKN2A mutations. Cancer Epidemiol Biomarkers Prev 14:2208–2212PubMed Goldstein AM, Landi MT, Tsang S, Fraser MC, Munroe DJ, Tucker MA (2005) Association of MC1R variants and risk of melanoma in melanoma-prone families with CDKN2A mutations. Cancer Epidemiol Biomarkers Prev 14:2208–2212PubMed
10.
Zurück zum Zitat van der Velden PA, Sandkuijl LA, Bergman W et al (2001) Melanocortin-1 receptor variant Arg151Cys modifies melanoma risk in Dutch families with melanoma. Am J Hum Genet 69:774–779. doi:10.1086/323411 CrossRefPubMed van der Velden PA, Sandkuijl LA, Bergman W et al (2001) Melanocortin-1 receptor variant Arg151Cys modifies melanoma risk in Dutch families with melanoma. Am J Hum Genet 69:774–779. doi:10.​1086/​323411 CrossRefPubMed
12.
13.
Zurück zum Zitat Matichard E, Verpillat P, Meziani R et al (2004) Melanocortin 1 receptor (MC1R) gene variants may increase the risk of melanoma in France independently of clinical risk factors and UV exposure. J Med Genet 41:e13. doi:10.1136/jmg.2003.011536 CrossRefPubMed Matichard E, Verpillat P, Meziani R et al (2004) Melanocortin 1 receptor (MC1R) gene variants may increase the risk of melanoma in France independently of clinical risk factors and UV exposure. J Med Genet 41:e13. doi:10.​1136/​jmg.​2003.​011536 CrossRefPubMed
14.
Zurück zum Zitat Palmer JS, Duffy DL, Box NF et al (2000) Melanocortin-1 receptor polymorphisms and risk of melanoma: is the association explained solely by pigmentation phenotype? Am J Hum Genet 66:176–186. doi:10.1086/302711 CrossRefPubMed Palmer JS, Duffy DL, Box NF et al (2000) Melanocortin-1 receptor polymorphisms and risk of melanoma: is the association explained solely by pigmentation phenotype? Am J Hum Genet 66:176–186. doi:10.​1086/​302711 CrossRefPubMed
18.
Zurück zum Zitat Ali-Osman F, Akande O, Antoun G, Mao JX, Buolamwini J (1997) Molecular cloning, characterization, and expression in Escherichia coli of full-length cDNAs of three human glutathione S-transferase Pi gene variants. Evidence for differential catalytic activity of the encoded proteins. J Biol Chem 272:10004–10012. doi:10.1074/jbc.272.15.10004 CrossRefPubMed Ali-Osman F, Akande O, Antoun G, Mao JX, Buolamwini J (1997) Molecular cloning, characterization, and expression in Escherichia coli of full-length cDNAs of three human glutathione S-transferase Pi gene variants. Evidence for differential catalytic activity of the encoded proteins. J Biol Chem 272:10004–10012. doi:10.​1074/​jbc.​272.​15.​10004 CrossRefPubMed
19.
Zurück zum Zitat Casilli F, Di Rocco ZC, Gad S et al (2002) Rapid detection of novel BRCA1 rearrangements in high-risk breast-ovarian cancer families using multiplex PCR of short fluorescent fragments. Hum Mutat 20:218–226. doi:10.1002/humu.10108 CrossRefPubMed Casilli F, Di Rocco ZC, Gad S et al (2002) Rapid detection of novel BRCA1 rearrangements in high-risk breast-ovarian cancer families using multiplex PCR of short fluorescent fragments. Hum Mutat 20:218–226. doi:10.​1002/​humu.​10108 CrossRefPubMed
21.
Zurück zum Zitat Goldstein AM, Chaudru V, Ghiorzo P et al (2007) Cutaneous phenotype and MC1R variants as modifying factors for the development of melanoma in CDKN2A G101W mutation carriers from four countries. Int J Cancer 121:825–831. doi:10.1002/ijc.22712 CrossRefPubMed Goldstein AM, Chaudru V, Ghiorzo P et al (2007) Cutaneous phenotype and MC1R variants as modifying factors for the development of melanoma in CDKN2A G101W mutation carriers from four countries. Int J Cancer 121:825–831. doi:10.​1002/​ijc.​22712 CrossRefPubMed
22.
Zurück zum Zitat Dolzan V, Rudolf Z, Breskvar K (2006) Genetic susceptibility to environmental carcinogenesis in Slovenian melanoma patients. Acta Dermatovenerol Alp Panonica Adriat 15:69–78PubMed Dolzan V, Rudolf Z, Breskvar K (2006) Genetic susceptibility to environmental carcinogenesis in Slovenian melanoma patients. Acta Dermatovenerol Alp Panonica Adriat 15:69–78PubMed
23.
Zurück zum Zitat Mossner R, Anders N, Konig IR et al (2007) Variations of the melanocortin-1 receptor and the glutathione-S transferase T1 and M1 genes in cutaneous malignant melanoma. Arch Dermatol Res 298:371–379. doi:10.1007/s00403-006-0708-7 CrossRefPubMed Mossner R, Anders N, Konig IR et al (2007) Variations of the melanocortin-1 receptor and the glutathione-S transferase T1 and M1 genes in cutaneous malignant melanoma. Arch Dermatol Res 298:371–379. doi:10.​1007/​s00403-006-0708-7 CrossRefPubMed
25.
Zurück zum Zitat Kanetsky PA, Holmes R, Walker A et al (2001) Interaction of glutathione S-transferase M1 and T1 genotypes and malignant melanoma. Cancer Epidemiol Biomarkers Prev 10:509–513PubMed Kanetsky PA, Holmes R, Walker A et al (2001) Interaction of glutathione S-transferase M1 and T1 genotypes and malignant melanoma. Cancer Epidemiol Biomarkers Prev 10:509–513PubMed
26.
Zurück zum Zitat Shanley SM, Chenevix-Trench G, Palmer J, Hayward N (1995) Glutathione S-transferase GSTM1 null genotype is not overrepresented in Australian patients with nevoid basal cell carcinoma syndrome or sporadic melanoma. Carcinogenesis 16:2003–2004. doi:10.1093/carcin/16.8.2003 CrossRefPubMed Shanley SM, Chenevix-Trench G, Palmer J, Hayward N (1995) Glutathione S-transferase GSTM1 null genotype is not overrepresented in Australian patients with nevoid basal cell carcinoma syndrome or sporadic melanoma. Carcinogenesis 16:2003–2004. doi:10.​1093/​carcin/​16.​8.​2003 CrossRefPubMed
27.
Zurück zum Zitat Lafuente A, Molina R, Palou J, Castel T, Moral A, Trias M (1995) Phenotype of glutathione S-transferase Mu (GSTM1) and susceptibility to malignant melanoma. MMM group. Multidisciplinary Malignant Melanoma Group. Br J Cancer 72:324–326PubMed Lafuente A, Molina R, Palou J, Castel T, Moral A, Trias M (1995) Phenotype of glutathione S-transferase Mu (GSTM1) and susceptibility to malignant melanoma. MMM group. Multidisciplinary Malignant Melanoma Group. Br J Cancer 72:324–326PubMed
32.
Zurück zum Zitat Rebbeck TR (1997) Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility. Review. Cancer Epidemiol Biomarkers Prev 6:733–743PubMed Rebbeck TR (1997) Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility. Review. Cancer Epidemiol Biomarkers Prev 6:733–743PubMed
35.
Zurück zum Zitat Pavey S, Gabrielli B (2002) Alpha-melanocyte stimulating hormone potentiates p16/CDKN2A expression in human skin after ultraviolet irradiation. Cancer Res 62:875–880PubMed Pavey S, Gabrielli B (2002) Alpha-melanocyte stimulating hormone potentiates p16/CDKN2A expression in human skin after ultraviolet irradiation. Cancer Res 62:875–880PubMed
36.
Zurück zum Zitat García-Borrón JC, Sánchez-Laorden BL, Jiménez-Cervantes C (2005) Melanocortin-1 receptor structure and functional regulation. Pigment Cell Res 18:393–410PubMed García-Borrón JC, Sánchez-Laorden BL, Jiménez-Cervantes C (2005) Melanocortin-1 receptor structure and functional regulation. Pigment Cell Res 18:393–410PubMed
Metadaten
Titel
Protective effect of copy number polymorphism of glutathione S-transferase T1 gene on melanoma risk in presence of CDKN2A mutations, MC1R variants and host-related phenotypes
verfasst von
Valérie Chaudru
M. T. Lo
F. Lesueur
C. Marian
H. Mohamdi
K. Laud
M. Barrois
A. Chompret
M. F. Avril
F. Demenais
B. Bressac-de Paillerets
Publikationsdatum
01.12.2009
Verlag
Springer Netherlands
Erschienen in
Familial Cancer / Ausgabe 4/2009
Print ISSN: 1389-9600
Elektronische ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-009-9249-5

Weitere Artikel der Ausgabe 4/2009

Familial Cancer 4/2009 Zur Ausgabe

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

13.05.2024 Pankreaskarzinom Nachrichten

Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

12.05.2024 Prostatakarzinom Nachrichten

Ein hoher Anteil pflanzlicher Nahrung trägt möglicherweise dazu bei, das Progressionsrisiko von Männern mit Prostatakarzinomen zu senken. In einer US-Studie war das Risiko bei ausgeprägter pflanzlicher Ernährung in etwa halbiert.

Alter verschlechtert Prognose bei Endometriumkarzinom

11.05.2024 Endometriumkarzinom Nachrichten

Ein höheres Alter bei der Diagnose eines Endometriumkarzinoms ist mit aggressiveren Tumorcharakteristika assoziiert, scheint aber auch unabhängig von bekannten Risikofaktoren die Prognose der Erkrankung zu verschlimmern.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.